Perrigo Company PRGO today announced that it has begun commercial shipments of
betamethasone valerate foam 0.12%, the generic equivalent of Luxiq®
Foam, consistent with the date certain launch settlement previously announced.
Cobrek Pharmaceuticals, Inc. ("Cobrek"), which was recently acquired by
Perrigo, was first to file, making the product eligible for 180 days of
marketing exclusivity. Perrigo is entitled to receive 100% of the profits from
net sales of the product due to the Cobrek acquisition.
Betamethasone valerate foam 0.12% is indicated for the relief of
corticosteroid-responsive skin conditions of the scalp (scalp psoriasis).
Brand annual sales were approximately $40 million as measured by Symphony
Health.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in